4/A: Keros Therapeutics CFO Amends SEC Filing to Correct Transaction Dates

Keith Regnante, CFO of Keros Therapeutics, files an amendment to a Form 4, correcting the dates of transactions involving common stock.

Summary

• Keith Regnante, the CFO of Keros Therapeutics, filed an amended Form 4 with the SEC.
• The amendment corrects the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I.
• The original filing contained errors in the transaction dates.
• The corrected filing shows transactions that occurred on January 4, 2024.
• These transactions involved the acquisition and disposition of 40,000 shares of Keros Therapeutics common stock each.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on March 8, 2023.
• The sale price was $45.29 and the purchase price was $16.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.

Industry Context

This filing is a routine disclosure related to insider trading activity and is common for publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to trade company stock while avoiding accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, with executives and major shareholders required to report transactions in their company's stock.
• The use of Rule 10b5-1 trading plans is a common and accepted method for corporate insiders to manage their stock holdings while mitigating the risk of insider trading allegations.
• Many companies such as Amgen, Biogen, and Regeneron have executives who utilize 10b5-1 plans.

Key Dates